Standing on the shoulders of giants: a retrospective analysis of kinase drug discovery at AstraZeneca

Drug Discovery Today

Volumn 21, Issue 10, 2016, Pages 1596-1608

  Kettle, Jason G ^a   Wilson, David M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINOQUINAZOLINE; AZD 0424; AZD 1719; AZD 3841; BARASERTIB; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; OSIMERTINIB; PHOSPHOTRANSFERASE INHIBITOR; QUINOLINE DERIVATIVE; SARACATINIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

DRUG ACTIVITY; DRUG RESEARCH; DRUG SCREENING; ENZYME INHIBITION; PATENT; RETROSPECTIVE STUDY; REVIEW; ANIMAL; DRUG DEVELOPMENT; DRUG INDUSTRY; HUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; QUINOLINES;

EID: 84991333684     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.06.007     Document Type: Review

References (65)

1. 1 Ding, M., (eds.) Innovation and Marketing in the Pharmaceutical Industry Emerging Practices, Research and Policies, 2014, Springer.
2. 2 Wu, P., et al. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36 (2015), 422–439.
3. 3 Wu, P., et al. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov. Today 21 (2016), 5–10.
4. 4 Ward, W.H.J., et al. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 48 (1994), 659–666.
5. 5 Shewchuk, L., et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 43 (2000), 133–138.
6. 6 Barker, A.J., et al. Studies leading to the identification of ZD1839 (IRESSA™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11 (2001), 1911–1914.
7. 7 Ballard, P., et al. Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics. Bioorg. Med. Chem. Lett. 16 (2006), 4908–4912.
8. 8 Ran, Y., Yalkowsky, S.H., Prediction of drug solubility by the general solubility equation (GSE). J. Chem. Inf. Comput. Sci. 41 (2001), 354–357.
9. 9 Barlaam, B., et al. Discovery of AZD8931, an equipotent, reversible inhibitor of signalling by EGFR, HER2, and HER3 receptors. ACS Med. Chem. Lett. 4 (2013), 742–746.
10. 10 Hickinson, M.D., et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin. Cancer Res. 16 (2010), 1159–1169.
11. 11 Baselga, J., et al. Abstract LB-146: a Phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, plus paclitaxel (P) vs P alone in patients (pts) with low HER2-expressing advanced breast cancer (BC) (THYME). Cancer Res., 73, 2013, LB-146.
12. 12 Johnston, S.R.D., et al. Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT). J. Clin. Oncol., 31, 2013 abstract 531.
13. 13 Tjulandin, S., et al. Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Invest. New Drugs 32 (2014), 145–153.
14. 14 Zeng, Q., et al. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). J. Med. Chem. 58 (2015), 8200–8215.
15. 15 Wedge, S.R., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65 (2005), 4389–4400.
16. 16 Bhide, R.S., et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J. Med. Chem. 49 (2006), 2143–2146.
17. 17 Cai, Z-W., et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J. Med. Chem. 51 (2008), 1976–1980.
18. 18 Mulders, P., et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised Phase II study. Eur. J. Cancer 48 (2012), 527–537.
19. 19 Ledermann, J.A., et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, palcebo-controlled phase 3 trial. Lancet 387 (2016), 1066–1074.
20. 20 Parson, S.J., Parsons, J.T., Src family kinases, key regulators of signal transduction. Oncogene 23 (2004), 7906–7909.
21. 21 Martin, S.G., The road to Src. Oncogene 23 (2004), 7910–7917.
22. 22 Plé, P.A., et al. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J. Med. Chem. 47 (2004), 871–887.
23. 23 Hennequin, L.F., et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 49 (2006), 6465–6488.
24. 24 Mackay, A.J., et al. A Phase II trial of the Src kinase inghibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH Phase II consortium. Invest. New Drugs 30 (2012), 1158–1163.
25. 25 Lara, P.N. Jr., et al. A Phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anti Cancer Drug 20 (2009), 179–184.
26. 26 Gucalp, A., et al. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin. Breast Cancer 11 (2011), 306–311.
27. 27 McNeish, I.A., et al. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Ann. Oncol. 25 (2014), 1988–1995.
28. 28 Kaufman, A.C., et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann. Neurol. 77 (2015), 953–971.
29. 29 Nygaard, H.B., et al. A Phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease. Alzheimers Res. Ther., 7, 2015, 35.
30. 30 Lengauer, C., et al. Genetic instabilities in human cancers. Nature 396 (1998), 643–649.
31. 31 Bischoff, J.R., et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17 (1998), 3052–3065.
32. 32 Keen, N., Taylor, S., Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4 (2004), 927–936.
33. 33 Heron, N.M., et al. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 16 (2006), 1320–1323.
34. 34 Jung, F.H., et al. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J. Med. Chem. 49 (2006), 955–970.
35. 35 Mortlock, A.A., et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase. J. Med. Chem. 50 (2007), 2213–2224.
36. 36 Kantarjian, H.M., et al. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin. Lymphoma Myeloma Leuk. 13 (2013), 559–567.
37. 37 Dennis, M., et al. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. Cancer Chemother. Pharmacol. 70 (2012), 461–469.
38. 38 Ashton, S., et al. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci. Transl. Med., 8, 2016, 325ra17.
39. 39 Ballard, P., et al. Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorg. Med. Chem. Lett. 17 (2007), 6326–6329.
40. 40 Ballard, P., et al. 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorg. Med. Chem. Lett. 15 (2005), 4226–4229.
41. 41 Barlaam, B., et al. Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorg. Med. Chem. Lett. 18 (2008), 1799–1803.
42. 42 Lynch, T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004), 2129–2139.
43. 43 Paez, J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
44. 44 Pao, W., et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 13306–13311.
45. 45 Mok, T.S., et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 (2009), 947–957.
46. 46 Douillard, J-Y., et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a Phase-IV, open-label, single-arm study. Br. J. Cancer 110 (2014), 55–62.
47. 47 Sherr, C.J., Cancer cell cycles. Science 274 (1996), 1672–1677.
48. 48 Fisher, R.P., The CDK network: linking cycles of cell division and gene expression. Genes Cancer 3 (2013), 731–738.
49. 49 Anderson, M., et al. Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation. Bioorg. Med. Chem. Lett. 13 (2003), 3021–3026.
50. 50 Byth, K.F., et al. Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett 14 (2004), 2245–2248.
51. 51 Anderson, M., et al. Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 20 (2008), 5487–5492.
52. 52 Camidge, D.R., et al. A first-in-man Phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers. Cancer Chemother. Pharmacol. 60 (2007), 391–398.
53. 53 Camidge, D.R., et al. A Phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers. Cancer Chemother. Pharmacol. 60 (2007), 479–488.
54. 54 Boss, D.S., et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Ann. Oncol. 21 (2010), 884–894.
55. 55 Toogood, P.L., et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J. Med. Chem. 48 (2005), 2388–2406.
56. 56 Witt, A., et al. A novel scalable process to the GSK3β inhibitor AZD8926 based on a heterocyclic Ziegler coupling. Org. Process Res. Dev. 17 (2013), 672–678.
57. 57 Ducray, R., et al. Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase. Bioorg. Med. Chem. Lett. 21 (2011), 4698–4701.
58. 58 Ducray, R., et al. Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: optimization of the aniline. Bioorg. Med. Chem. Lett. 21 (2011), 4702–4704.
59. 59 Degorce, S.L., et al. Discovery of a potent, selective, orally bioavailable and efficacious novel 2-(pyrazol-4-ylamino)-pyrimidine inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). J. Med. Chem. 59 (2016), 4859–4866.
60. 60 Chen, H.X., Sharon, E., IGF-1R as an anti-cancer target – trials and tribulations. Chin. J. Cancer 32 (2013), 242–252.
61. 61 Pillai, R.N., Ramalingam, S.S., Inhibition of insulin-like growth factor receptor: end of a targeted therapy?. Transl. Lung Cancer Res. 2 (2013), 14–22.
62. 62 Ward, R.A., et al. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J. Med. Chem. 56 (2013), 7025–7048.
63. 63 Finlay, M.R.V., et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 57 (2014), 8249–8267.
64. 64 Remon, J., Planchard, D., AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Future Oncol. 11 (2015), 3069–3081.
65. 65 Integrity database from Thomson Reuters. Illustration reproduced and adapted using Cell Signalling Technology ( http://www.cellsignal.com).